President Donald Trump on Friday signed an executive order in Austin, Texas, reclassifying marijuana as a less dangerous drug and changing federal regulation and research of the substance.
The order directs federal agencies to move marijuana to a lower schedule under the Controlled Substances Act, easing restrictions that had limited research, clinical trials, and pharmaceutical development. Federal health and justice officials began reviewing current regulations immediately after the signing.
Supporters said the reclassification could expand scientific studies, boost medical research, and pave the way for new therapeutic products derived from cannabis. Researchers noted that more institutions could now apply for federal approval to conduct clinical trials.
Law enforcement officials and policy analysts warned the change could create new challenges at federal, state, and local levels. Public health experts cautioned that reduced federal restrictions could increase use among young adults without adequate prevention measures.
The executive order instructs federal agencies to issue updated rules and guidance within a set timeline, which the administration has not yet publicly specified.
